ZUPLENZ provides trusted ondansetron efficacy that’s portable, flexible, and dissolves in seconds

- A unique film strip formulation with bioequivalence to ondansetron ODT\textsuperscript{15,16}
  — Proven, non-sedating efficacy under fed and fasting conditions\textsuperscript{15,16}
- Dissolves in seconds with or without water\textsuperscript{15,16}
  — Maximum concentration of ondansetron is seen between 1.3 and 1.7 hours post dose\textsuperscript{15,16}

Prevention of nausea and vomiting is necessary, but can be uncomfortable

- With proper use of antiemetics, chemotherapy-induced nausea and vomiting can be prevented in 70\% to 80\% of patients\textsuperscript{3}
- Oral tablet antiemetics are often difficult to administer to patients with swallowing difficulties\textsuperscript{2}
- Intravenous antiemetics can’t be administered in an outpatient setting\textsuperscript{2}

ZUPLENZ Important Safety Information

- ZUPLENZ is contraindicated in patients who are concomitantly using apomorphine. Concomitant use of ZUPLENZ and apomorphine may result in profound hypotension and loss of consciousness.
- ZUPLENZ is contraindicated in patients with a known hypersensitivity to ondansetron as anaphylactic reactions have been known to occur.
- ZUPLENZ may mask a progressive ileus and/or gastric distention in patients following abdominal surgery or in patients with chemotherapy-induced nausea and vomiting.
- Patients with severe hepatic impairment (Child-Pugh score of 10 or greater) should not receive more than 8mg of ZUPLENZ per day due to a reduction in drug clearance.

ZUPLENZ provides a non-gritty alternative for patients who have dry mouth or difficulty swallowing

- Much like a breath-freshening strip, ultrathin, flexible film is not gritty
- ZUPLENZ film is only 100 microns thick

Discreet, “on-the-go” administration accommodates treatment schedules

- Individually wrapped strips are portable and can go almost anywhere patients go
- ZUPLENZ may be taken with or without water or food\textsuperscript{15,16}
- For use before or after treatment

\*CINV, chemotherapy-induced nausea and vomiting; RINV, radiation-induced nausea and vomiting; PONV, postoperative nausea and vomiting.

ZUPLENZ Important Safety Information

- Patients receiving ondansetron have experienced ECG changes including QT interval prolongation, including cases of Torsade de Pointes. ZUPLENZ should be used with caution in patients with electrolyte abnormalities, congestive heart failure, bradyarrhythmias or patients taking other medications that can lead to QT interval prolongation. ZUPLENZ should not be used in patients with congenital long QT syndrome.
- Hypersensitivity reactions, including anaphylaxis and bronchospasm, have been reported in patients who have exhibited hypersensitivity to other selective 5-HT\textsubscript{3} receptor antagonists. Discontinue using ZUPLENZ at the first sign of hypersensitivity.
ZUPLENZ® (ondansetron) oral soluble film
Important Safety Information (continued)

• ZUPLENZ is a 5-HT₃ receptor antagonist indicated for prevention of nausea and vomiting associated with highly emetogenic chemotherapy in adults; initial and repeat courses of moderately emetogenic chemotherapy in adults and children aged 4 and up; following total body irradiation, single-high-dose fraction of radiotherapy to the abdomen, or daily fractions to the abdomen in adults; and post-operatively in adults.

• Serotonin syndrome has been reported in patients taking 5-HT₃ receptor agonists, with most cases being reported in patients taking serotonergic drugs concomitantly with ondansetron. Some of these cases were fatal. Some reported cases of serotonin syndrome occurred in patients who have overdosed on ondansetron alone.

• ZUPLENZ is Pregnancy Category B and should only be used during pregnancy for the approved indications if clearly needed.

• The most common adverse events occurring in clinical trials of ondansetron in CINV and RINV patients included: headache, malaise/fatigue, constipation and diarrhea. The most common adverse events occurring in a clinical trial of ondansetron in PONV included: headache, hypoxia, pyrexia, dizziness, gynecological disorder, anxiety/agitation, urinary retention, and pruritus. In the PONV study, only headache was statistically more significant than adverse events seen in placebo patients.

• ZUPLENZ has been shown to be safe and effective for use in pediatric patients 4 years of age and older who are undergoing moderately emetogenic cancer chemotherapy. It has not been proven safe and effective in any other pediatric indication.